Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform
LAS VEGAS, NEVADA / ACCESS Newswire / May 27, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are exploring options to integrate the early detection of dementia into Ainnova's proprietary, AI-powered platform technology, Vision AI. The addition would reinforce the Company's mission of expanding AI-powered early detection and preventative health solutions across the globe.
Currently, the Company has identified a promising patented early disease detection technology specializing in the early detection of dementia and is exploring its options to either license the technology globally or potentially acquire the technology altogether. The patented technology combines AI algorithms and hardware based on a 5-minute blood test. Adding the early detection of dementia would expand the offerings in the Company's technology portfolio and enhance the broader vision of the partnership between Avant and Ainnova.
The success of the Company's preventative screening platform involves the deployment of an automated, low-cost retinal imaging device integrated with the Vision AI platform to deliver comprehensive preventive risk screening. Presently, from just two retinal images, blood pressure and some lab test information, the Company's system uses 4 integrated algorithms to assess risks for: (i) cardiovascular disease (CVD), (ii) type 2 diabetes, (iii) liver fibrosis, and (iv) chronic kidney disease (CKD).
Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the potential expansion of its technology portfolio, "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years. Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection."
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAIhttps://www.linkedin.com/company/avant-technologies-aihttps://www.facebook.com/AvantTechAIhttps://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies Inc.info@avanttechnologies.com
SOURCE: Avant Technologies Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Drug maker Indivior to abandon London stock market for the US
Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company to abandon the UK market for the US. However, the LSE welcomes Anglo-American's platinum spin-off Valterra after becoming independent from the mining giant. Indivior's exit comes after the company moved its primary listing to the US's Nasdaq index last year. It said cancelling the secondary listing in London eliminates 'cost and complexity' and better reflects the business – with more than 80% of its revenues generated in the US. It also said liquidity on the Nasdaq now 'far outweighs' that of the LSE with a greater level of trading. The US-based pharmaceutical firm makes prescription medicines to treat opioid addiction, and has a market capitalisation of £1.2 billion. 'A single primary listing on Nasdaq best reflects the profile of Indivior's business,' chairman David Wheadon said. 'We appreciate the support received from shareholders for this initiative and look forward to capitalising on the expected benefits of this move, including reductions in cost and complexity.' The LSE faced the largest exodus of companies since the global financial crisis in 2024, according to EY analysis. There were 88 companies to delist or transfer their primary listing from the main market – the most since 2009. At the same time, the LSE struggled to attract as many new companies to fill the gaps – with 18 new listings in total last year. Nevertheless, Indivior's exit, which will take effect from July 25, comes as Valterra Platinum makes its debut on the London market. Anglo American spun off its platinum business into the new entity, which has become the world's most valuable producer of the metal. Valterra will have its secondary listing on the LSE, with its primary on the Johannesburg Stock Exchange. Duncan Wanblad, Anglo American's chief executive, said: 'Valterra Platinum has been a major part of the company for many years but now is the right time for it to optimise its value creation prospects on an independent path – it's an outstanding business and team and I have every confidence that Valterra Platinum will thrive as a leader in the global platinum group metals industry.' Sign in to access your portfolio
Yahoo
9 minutes ago
- Yahoo
XSQUARE Technologies and Alkhorayef Commercial Company Sign MoU to Advance Saudi Arabia's Logistics Landscape
SINGAPORE, June 2, 2025 /PRNewswire/ -- Singapore-based XSQUARE Technologies and Alkhorayef Commercial Company (ACC), a leading integrated commercial and industrial solutions provider in the Kingdom of Saudi Arabia, have signed a Memorandum of Understanding (MoU) to establish a strategic framework for collaboration aimed at accelerating the adoption of intelligent warehouse automation and transforming intralogistics operations across Saudi Arabia. The signing took place at the Saudi Warehousing & Logistics Expo 2025. The MoU seeks to integrate ACC's growing logistics capabilities and XSQUARE's next-generation intelligent warehouse automation solutions – comprising a suite of Autonomous Mobile Robots (AMRs) and a warehouse orchestration software – to deliver a high-performance, safe, and scalable intralogistics solutions for the Saudi market. Under the agreement, both companies will collaborate on joint market outreach and the deployment of customisable end-to-end automation solutions across key logistics and industrial hubs. The partnership will also include the development of pilot projects and demonstrations to showcase the operational efficiencies and economic benefits of AMR-enabled logistics. Fahad AlJaddan, CEO of Alkhorayef Commercial Company, commented: "This partnership marks a significant step forward in our journey to shape the future of logistics in Saudi Arabia. By working with XSQUARE Technologies, we are bringing cutting-edge automation into our ecosystem and empowering our customers with solutions that are efficient, intelligent, and built for scale. We look forward to advancing Saudi Arabia's logistics landscape in support of Vision 2030's agenda." As part of its commitments, ACC will leverage its strong local presence and logistics expertise to support the deployment of XSQUARE's automation technologies. This includes promoting AMRs as solutions to key customers and providing commercial insights to guide market adaptation. XSQUARE Technologies, in turn, will provide technical enablement and integration support, including training, product documentation, and solution roadmaps. The company will also provide access to dedicated experts to support localisation efforts and execute pilot projects. Jens Bohnwagner, CEO of XSQUARE Technologies, commented:"Partnering with ACC will allow us to bring our proven automation technologies into a rapidly evolving market with immense potential. As a respected leader in the region's logistics sector with deep market knowledge and operational excellence, ACC is an ideal partner in our journey. We see this collaboration as a powerful platform to demonstrate both the impact and adaptability of our warehouse automation solutions to the specific demands of Saudi Arabia and the region." The MoU is a clear demonstration of both companies' shared commitment to a long-term partnership dedicated to driving the transformation of Saudi Arabia's logistics sector through innovation and adaptability. About XSQUARE Technologies XSQUARE Technologies is at the forefront of the logistics revolution, offering cutting-edge warehouse automation solutions across Asia Pacific and beyond. Backed by Goldbell Group's 40 years of expertise, we offer a suite of Autonomous Forklifts and Intelligent Warehouse Orchestrator software that set new standards in interoperability and efficiency, simplifying warehouse operations without the need for extensive reconfiguration and thus saving time and costs. Spanning a diverse range of industries from pharmaceuticals to manufacturing, we have a rapidly growing clientele that benefits from our innovation-driven, real-world-tested solutions. Visit to learn more. About Alkhorayef Commercial Company (ACC) Alkhorayef Commercial (ACC), established in 1957, is a provider of integrated industrial solutions across key sectors, including agriculture, logistics, marine, and entertainment in Saudi Arabia. Through partnerships with global brands, ACC supplies high-quality products and comprehensive aftersales services to enhance efficiency, reliability, and sustainability. Visit to learn more. View original content to download multimedia: SOURCE XSQUARE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks Defence Therapeutics' initial physical presence in the United States, reinforcing its commitment to advancing cutting-edge research and development in one of the world's foremost biotech clusters. The new laboratory, located at Cambridge Scientific Labs in Watertown, will allow Defence Therapeutics to further develop and optimize its proprietary Accum® technology for antibody-drug conjugates ("ADCs"). Establishing a presence in the Boston-Cambridge area provides the company with access to top-tier scientific resources and opportunities for collaboration within the region's renowned biotech ecosystem. The Cambridge Scientific Labs location will serve as a short-term base while Defence Therapeutics evaluates options for a long-term facility in the area. "Our expansion into the Boston-Cambridge area is a significant milestone for Defence Therapeutics," said Sebastien Plouffe, CEO of Defence Therapeutics. "Establishing a U.S. laboratory positions us at the heart of the global biotech community and supports our mission to advance the Accum® platform for next-generation ADCs. We look forward to deepening our presence in the region as we continue to grow and pursue a long-term facility in this dynamic market." About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer. For further information: Sebastien Plouffe, President, CEO and DirectorP: (514) 947-2272Splouffe@ Cautionary Statement Regarding "Forward-Looking" Information This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
